-
Mashup Score: 65-Year Safety Data From Upadacitinib Trials Reported - 3 month(s) ago
Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.
Source: www.medscape.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 1Real-World Data Demonstrate Safety, Efficacy of Upadacitinib for PsA - 5 month(s) ago
Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.
Source: www.hcplive.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Adolescents, Atopic Dermatitis, and Upadacitinib: Efficacy, Safety - 6 month(s) ago
Adolescents with moderate-to-severe atopic dermatitis (AD) saw major improvements after taking upadacitinib (Rinvoq) for 16 weeks, according to an analysis appearing recently in . The study combined data from three separate phase 3 studies, collectively taking place in more than 20 countries and comprising 552 adolescents (290 female; 262 male).
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Continuous Upadacitinib Treatment of Atopic Dermatitis Suggested to Ensure Maintenance of Skin Clearance - 7 month(s) ago
In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0MACE, malignancy risks similar for upadacitinib, adalimumab in rheumatoid arthritis - 8 month(s) ago
Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Upadacitinib Well Tolerated Across Multiple Inflammatory Conditions - 9 month(s) ago
In a recent study published in RMD Open, the long-term safety profile of upadacitinib, a medication utilized in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD), was evaluated.
Source: HMP Global Learning NetworkCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Roy Fleischmann, MD: Long-Term Safety, Efficacy of Upadacitinib for Rheumatoid Arthritis Treatment - 10 month(s) ago
Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Iain McInnes, CBE, PhD: Long-Term Efficacy, Safety of Upadacitinib in Patients With Psoriatic Arthritis - 10 month(s) ago
Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Xenofon Baraliakos, MD, PhD: Efficacy of Upadacitinib for Treating Active Ankylosing Spondylitis - 10 month(s) ago
Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Xenofon Baraliakos, MD, PhD: Efficacy of Upadacitinib for Treating Active Ankylosing Spondylitis - 10 month(s) ago
Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
5-Year Safety Data From #Upadacitinib Trials Reported https://t.co/hC6qL5YuS0